pharmaceutical industry Archives - Business Intelligence

Tag: pharmaceutical industry

Drug Development Process + Product Research

Simplifying the Drug Development Process with Expert Insights and Product Research Solutions

In an industry as competitive as the pharmaceutical industry, innovation is the best strategy for success. Unfortunately, innovation in this industry is a challenging process. The drug development process is a long, taxing, and exhaustive process, regardless of the size of a company. Although the process becomes easier with more available resources, workforce, and a better understanding of the regulatory requirements, many major pharma companies may still struggle to complete the process without experts’ guidance.

The drug development process across the world is divided into various phases, starting from drug discovery to post-marketing safety surveillance. There are five phases of drug development in the United States, including discovery, research, and acquiring regulatory approval from the US Food and Drug Administration (FDA).

Many top pharmaceutical companies leverage market research services and product research solutions to ensure an effective drug development process. In this article, Infiniti’s experts discuss the five phases of the drug development process and the value of product research services during each phase.

The pharmaceutical industry is highly competitive, and companies must prepare for every aspect of competing in this market. Speak to our industry experts to learn how Infiniti’s solutions can help pharmaceutical companies stay ahead of the curve.

Five Phases of the Drug Development Process and How Infiniti’s Product Research Services Can Help

Infiniti’s experts analyzed the drug development process in the US pharmaceutical process and identified the following five phases of drug development:

Discovery and Development

The first phase of the drug development process is the discovery of a hit compound. Academic and industry scientists identify a potential target for any disease and aim to discover and develop a compound that can alter the druggable target activity. A target is considered druggable if it can be changed or treated by therapeutic agents. Various screening methods such as phenotypic screening or fragment-based screening are then used to identify a hit compound, and the effect of the said compound is analyzed. Multiple hit compounds may be used to address the same or various druggable targets for a disease. To determine the drug candidate that the scientists choose to take forward as a clinical candidate, they must ensure that it affects the selective target, generates the desired effect, and has adequate bioavailability. Additionally, it must have a toxicity profile, manufacturing suitability, and cost-effectiveness.

Product research solutions enable companies to evaluate and understand this phase of discovery and development. With advice from Infiniti’s product research experts, companies gain in-depth insights into the scalability of the clinical candidate and illustrative guidance regarding the cost-effectiveness of their drug. Additionally, with data-driven insights, scientists can identify unmet needs and target the ideal population, and companies can analyze competitors’ targets.  

Preclinical Research

The second phase of drug development involves proving the efficacy and safety of the drug candidate. In vitro and in vivo testing methods are utilized to study the candidate’s biological effects. This includes testing animal models and evaluating the impact on a species with a similar genetic makeup. To acquire approval from regulatory bodies, such as the US FDA, it is crucial to conduct this research while considering species-specific physiology and sex-specific responses in the animals. The FDA provides a specific set of regulations for the second phase of the drug development process. These regulations include basic requirements for personnel, facilities, equipment, and more. While preclinical studies are short, they must provide information regarding toxicity and dosing levels. This helps the researchers determine if the drug candidate meets preclinical requirement levels and can be tested on human subjects.

With guidance from product research experts, researchers and companies can attain crucial information regarding regulatory requirements. They can also understand the strategies, technologies, and equipment leveraged by their competitors, and always remain a step ahead. Additionally, product research solutions can enable companies to identify gaps in their offerings or operations and address them by developing data-driven strategies.

Clinical Research

Designing an effective clinical trial requires rigorous research, planning, and studying. Researchers must develop a specific protocol or plan, review preliminary information about the clinical candidate, and accordingly develop research questions and objectives. This information helps the researchers decide various important factors, such as selection criteria, number of participants, length of the study, administration and dosages, methods of collection, and data analysis. One of the crucial stages of the clinical research phase is submitting an Investigational New Drug (IND) Application. There are three kinds of IND applications, investigator, emergency use, and treatment. The FDA team has 30 days to review the IND application and respond in one of two ways, approval, or a clinical hold to delay or stop the investigation. The clinical research stage of the drug development process has between three to four phases within it, which depends on the protocol decided by the researcher. Obtaining guidance from the FDA at this stage of the process is possible, including extensive technical assistance, if a drug developer chooses to leverage the aid.

Infiniti’s product research experts can enable companies to design an effective clinical trial protocol, gain a comprehensive understanding of the FDA guidance and approval requirements. Further, researchers can analyze and evaluate the factors being taken into consideration regarding the clinical trial design with expert guidance. Additionally, the drug developers will receive recommendations and directions regarding the crucial IND application.

The drug development process is challenging and long drawn. To learn more about the process, and overcoming obstacles with product research solutions, request more information.

Drug Development Process + Product Research

FDA Drug Review

Once a researcher or company has evidence regarding the drug’s safety and efficacy, they may file a New Drug Application (NDA) to market the drug with the FDA. This application includes all the relevant data from the preclinical and clinical research phases. The application should consist of details regarding the proposed labeling, safety updates, drug abuse information, patent information, directions for use, and more. The FDA then reviews all the details of the application. In the case that the application is incomplete, they will refuse to file the NDA. If it is complete, the FDA review team can take between 6 to 10 months to review the drug and the data and decide to approve it. This process includes a thorough review of each section by the relevant team member, routine inspections of clinical study sites across the country, and the compilation of all reviews and documents into an “action package.” Often, there is a set of issues that need to be resolved before the FDA approves the drug. In certain cases, resolution may include conducting more studies, at which point the drug developers can decide if they want to complete the drug development process. In particular situations, the FDA may approach their advisory committees for independent, expert inputs and advice, including a representative to provide the patient perspective.

Infiniti’s product research solutions can enable drug developers to ensure the NDA is complete and qualifies for all the regulatory requirements. Additionally, our experts can provide researchers with crucial information regarding other patents in the market and the patent process. Product research solutions also help developers understand the patient’s perspective, ensure that their drug fulfills unmet needs, and is positively received by patients and representatives.

Approval and Post-Marketing Safety Surveillance

Once a drug has been approved, and companies begin manufacturing and marketing, the FDA continues to survey the drug in the market. This includes the announced or unannounced inspection of manufacturing facilities and regulations regarding prescription drug advertisements and promotional labeling. The post-marketing safety surveillance aims to evaluate the long-term efficacy and safety of the drug, potential problems that could arise outside of a controlled environment, and possible use for unapproved conditions. The FDA also has various programs that allow professionals, consumers, and manufacturers to report any issues associated with a drug. Additionally, the introduction of the Sentinel Initiative enables the FDA to use major existing electronic health databases to spot safety issues easily.

Product research solutions enable drug developers to stay a step ahead of the FDA regulations and ensure their drug meets all the requirements. Infiniti’s experts can also guide companies regarding the compounds, packagers, and manufacturers to ensure post-marketing safety with well-researched insights. Manufacturers can also learn about the ideal equipment and technologies for manufacturing the drug and the FDA regulatory requirements.

Final Thoughts

Infiniti’s product research solutions can enable companies to overcome the difficult drug development process’s various challenges. Our experts provide insights regarding regulatory requirements, ideal technologies, competitors’ strategies and patents, and consumers’ unmet needs. This offers companies and researchers a substantial strategic advantage, a clear plan through the five phases, and the post-marketing and manufacturing stages. With expert insights, experienced advice, and crucial data, drug developers can prepare, implement, and complete an efficient and safe drug development process.

Infiniti’s product research solutions can enable companies to overcome the drug development challenges and establish themselves as industry leaders. Request a free proposal to leverage Infiniti’s data-driven insights, expert guidance, and unparalleled strategies.

Pharmaceutical Value Chain + Market Intelligence

Restoring Normalcy in the Pharmaceutical Value Chain: The Impact of COVID-19 and the Next Step to Success

The COVID-19 pandemic has challenged industries, countries, and governments endlessly over recent months. The spread of the virus has led to a range of issues that impact the foundation and functioning of business operations, GDPs’, and supply chains. All industries are now working towards recovery, and the pharmaceutical industry is attempting to regain control and functionality across the pharmaceutical value chain.

The pharmaceutical value chain includes every component and every process from manufacturer to end-consumer. This includes, but is not limited to, manufacturing, acquiring regulatory approval, import and export, distribution, and retail. The safety regulations, nationwide lockdowns, and transportation disruptions caused by the COVID-19 pandemic are among the biggest factors impacting the pharmaceutical value chain.

Pharmaceutical companies have attempted to develop more streamlined processes and taken various initiatives prior to the COVID-19 pandemic due to the pharmaceutical value chain’s fragmented nature. However, few have succeeded, and the different strategies utilized by companies did not protect the value chain from the hard-hitting impact of the COVID-19 pandemic.

As the pharmaceutical industry focuses its effort towards recovering the pharmaceutical value chain, companies must understand the impact of the pandemic. Therefore, in this article, Infiniti’s market intelligence experts detail the effects of the COVID-19 crisis on the pharmaceutical value chain. Additionally, they discuss the best path to recovery for pharmaceutical companies and highlight the value of market intelligence solutions in this attempt to return to normalcy.

The pharmaceutical industry is on the path to recovery and companies need to strategize for the changing market dynamics and impact of the COVID-19 pandemic. Speak to our industry experts to learn how companies can develop the optimal strategies to face these challenges.

Impact of COVID-19 on the Pharmaceutical Value Chain

As is the case with most industries, there have been innumerable problems posed by the advent of the COVID-19 pandemic in the pharmaceutical value chain. However, three major segments have been severely impacted and will need the most focus and recovery strategies from pharmaceutical companies. The impact of the COVID-19 pandemic on the pharmaceutical value chain can be witnessed in the following three segments:

Pharmaceutical Value Chain + Market Intelligence

APIs and the Dependence on APAC Countries

The pharmaceutical industry’s raw material supply chain was disrupted by the high dependence of pharmaceutical companies on China and India. The two APAC countries source a majority segment of the active pharmaceutical ingredients (APIs), intermediates, and reagents required by pharma companies. Since China was the first infected country, the raw material supply chain was slightly challenged. However, the spread of the virus has impacted India severely and caused a major disruption in the pharmaceutical value chain.

While China is on the path to recovery and is attempting to return to normalcy, India has many obstacles to overcome before it can successfully overcome the impact of the COVID-19 crisis. Restoring operations and recovering from the effects of the pandemic will cost the pharmaceutical value chain a substantial amount of time and effort due to this factor.

Logistics and Distribution Challenges

Countries across the globe have announced nationwide lockdowns and severely limited domestic and international transportation. Although this step was crucial for the containment of this deadly virus, it has led to major logistical challenges across industries. The pharmaceutical value chain has been similarly impacted due to transportation and distribution limitations.

The fragmented nature of the pharmaceutical value chain is one of the reasons the transportation restrictions are impacting the industry severely. The process involves the procurement of various raw materials from different locations in the APAC, North American, and European regions. Additionally, the manufacturing, packaging, distribution, and retailing are conducted in various areas. With the continuous spread of the virus and government restrictions on population movement and transportation, pharmaceutical companies need to evaluate their distribution and logistics strategies to maintain business continuity.

Paused Clinical Trials and the Drug Development Process

A large number of clinical trials worldwide have been suspended, postponed, or halted since the advent of the COVID-19 pandemic. Stakeholders consider this the most impacted segment in the pharma industry. Due to the need for social distancing, the limitations on transport, and the requirements of new hygiene protocols, conducting clinical trials and collecting real-world evidence has been challenging for pharma companies. The halting of clinical trials translates into a delay in the development and time-to-market for various therapies and drugs.

Simultaneously, pharmaceutical companies are struggling to conduct clinical trials to develop a vaccine for the SARS-CoV-2 virus, which causes COVID-19. However, they face challenges finding ideal candidates and carrying out their clinical trials despite the various limitations. Pharma companies and governments are working towards digitalizing the clinical trial process with innovative alternatives such as telemedicine and mailing trial drugs. Efficiently digitalizing, and overcoming the various challenges caused by the COVID-19 pandemic will help companies develop a vaccine and fast-track recovery worldwide.

Understanding the impact of the COVID-19 pandemic on the pharmaceutical value chain is a crucial step for recovery in the pharmaceutical industry. Request more information to gain more in-depth insights into the challenges caused by the pandemic and the next step to recovery.

How can Market Intelligence Solutions help Pharmaceutical Companies Overcome the Impact of COVID-19?

Pharmaceutical companies need a series of solutions to assist them in their attempt to recover from the impact of the COVID-19 pandemic. The pharmaceutical value chain has been significantly disrupted through 2020, and by re-establishing normalcy soon, companies can minimize the long-term implications of the pandemic across the value chain.

Infiniti’s market intelligence solutions can provide companies with insights, guidance, and strategies to help their industry recover as quickly as possible. There are various crucial factors that pharma companies must focus on during the process of recovery, and Infiniti’s market intelligence solutions can help them adapt and recuperate as required. Our market intelligence experts can help pharma companies and the pharmaceutical value chain in the following crucial ways:

  • Companies must improve transparency on the various levels of the supply chain and identify alternative sources for the different raw materials or services that are unavailable. Infiniti’s demand planning solutions enable companies to provide visibility into their operations and supply chains required to make real-time decisions and keep stakeholders informed.
  • There is also an increasing need for companies to analyze their inventory, estimate the available inventory across the value chain, and attempt to continue production and delivery to customers. With Infiniti’s inventory management solutions, companies can try to fulfill customers’ demands despite the disruptions caused by the COVID-19 pandemic.
  • Pharmaceutical companies must also focus on understanding and strategizing for the changing demands of their consumers. With social distancing and new hygiene protocols, consumers have been less likely to renew their prescriptions. Infiniti’s demand management solutions can enable companies to predict, plan, and meet customer demands accurately.

The pharmaceutical industry can successfully recover the pharmaceutical value chain with efficient planning, management, and strategizing. Infiniti’s market intelligence solutions provide companies with the data-driven insights and expert guidance they require to efficiently overcome the impact of the COVID-19 pandemic across the value chain.

Infiniti’s market intelligence solutions can serve as the differentiator between a quick recovery and additional challenges for companies attempting to recover the pharmaceutical value chain. Request a free proposal to enter the post-COVID era as a pharmaceutical industry champion with our expert insights and guidance.

Pharmaceutical Manufacturing Companies + Market Entry

Breaking the Norm: Overcoming Barriers to Entry in the Pharmaceutical Manufacturing Industry

The pharmaceutical manufacturing industry is expected to witness substantial growth in the coming years due to various contributing factors. As lifestyles and habits change, awareness about health and wellness increase, and demand for immediate relief grows, the market is bound to continue growing. Due to advancements in the pharmaceutical and technological fields, there has been an increase in the average life expectancy globally. This directly translates to a larger population of elderly or geriatric individuals, and a continuous need for the pharmaceutical manufacturing industry.

Although awareness about health and wellness is growing, the prevalence of terminal and chronic diseases has grown substantially in recent years, and the need for pharmaceutical drug discovery and development has increased. The pharmaceutical manufacturing industry has also seen a rise in demand due to easy access in the market, with the increased availability of over-the-counter (OTC) medicines. With these market growth drivers, the industry has become a highly competitive space and is attempting to recover from the disruptions caused by the COVID-19 pandemic.

Additionally, pipeline players are now attempting to establish themselves in the recovering industry successfully. However, this industry is considered among the top 10 industries with the highest barriers to entry. Therefore, Infiniti’s market entry experts analyzed the market and identified the most significant barriers to entry in the pharmaceutical manufacturing industry.

With their in-depth analysis, the experts identified four significant barriers to entry, among many others. While identifying and understanding these barriers to entry is important, it is essentially the first step in the process of becoming an industry leader. Infiniti’s market entry analysis helps companies identify, evaluate, and efficiently maneuver the barriers to entry in the pharmaceutical manufacturing industry. In this article, Infiniti’s experts discuss the significant barriers to entry in the pharmaceutical manufacturing industry and highlight the benefits of our market entry analysis.

Entering a market as competitive as the pharmaceutical manufacturing industry is a challenging ordeal. Request a free proposal to successfully break the norm and overcome market entry barriers.

Pharmaceutical Manufacturing Market Entry Barriers

Every industry is plagued with various barriers to entry. Not only is the pharmaceutical manufacturing industry one among these industries, but it also stands among the top 10 most difficult industries to enter. Therefore, our market entry experts identified and evaluated the following four most significant barriers to entry in the pharmaceutical manufacturing industry:

Economies of Scale

The pharmaceutical manufacturing industry requires a well-established distribution network and appropriate infrastructure. This is challenging for new entries into a market and serves as a major barrier to entry. As large pharmaceutical companies dominate the industry, it is difficult for new companies to produce the same drugs at the exact costs and gain market share. Economies of scale play a role in industries such as this one, wherein producers manufacture large quantities of small products. Additionally, brand name recognition plays a crucial role in prescription drugs, particularly drugs with certain effects. Consumers will rarely if ever, choose a brand that is not widely acclaimed or trusted. Therefore, new companies struggle to establish a brand name and gain market share when competing with larger, established pharmaceutical manufacturing companies.

Regulations and Approval

The pharmaceutical manufacturing industry has highly stringent and continually increasing regulations. In the US, the Food and Drug Administration (FDA) takes an average of approximately 21 months to approve a new drug. All pharmaceutical drugs must gain all required regulatory approvals before marketing. Additionally, acquiring FDA approval has proven to be highly challenging, with an extremely low success rate. Obtaining the required approvals is long-drawn and can be extremely expensive for small or new pharmaceutical companies. More often than not, this waiting period allows well-established companies to replicate the product and file a 180-day market exclusivity patent, which in turn provides them with a temporary monopoly. Following this, establishing a monopoly for the new drug can pose a tremendous challenge for the newer company.

Investment Capital

Establishing the required infrastructure, conducting clinical trials, and acquiring all regulatory approvals is extremely expensive. As companies attempt to enter this highly competitive market, they must invest a substantial amount over multiple years. Clinical trials alone require large investments and can still not be approved by the FDA and its parallel administrations across the world. In the US, it can take between 10 to 15 years for a new drug to complete the research and development process, and still face the possibility of not being approved to prescribe for customers. These expenses can be higher depending on the purpose and components of the drug being developed. For new market entries, this translates into high levels of investment, over a prolonged period with no revenue, and the possibility of not gaining approval. Whereas, established pharmaceutical companies continue to earn revenue from previously approved drugs and have the infrastructure in place.

Intellectual Property and Patents

The legal aspect of pharmaceutical manufacturing is agreeably one of the most significant barriers to entry in this market for two reasons. Larger pharmaceutical companies have approved patents that enable them to legally stop new companies from entering the market without establishing a new drug. Additionally, acquiring a patent is a challenging process, and often, patents expire before new companies can acquire the regulatory and FDA approvals that are needed to market and distribute the drug. This enables larger companies to replicate the product and use their distribution and marketing networks to establish a monopoly with the new drug, making it more challenging for new companies to gain revenue and market share.

Request more information to gain more in-depth insights into the impact of investment, regulations, and patents on new companies in the pharmaceutical manufacturing industry.

Pharmaceutical Manufacturing Companies and Market Entry Analysis

Infiniti’s market entry analysis helps new pharmaceutical manufacturing companies identify market entry barriers. It also helps identify and capitalize on appropriate market opportunities and understand the market that they choose to expand into or enter. Infiniti’s market entry experts also help companies with the following:

  • Understanding the needs and expectations of customers, identifying and developing the ideal consumers-centric products that gain the trust of their consumer base
  • Identifying and planning for the most profitable segments of a market, and making optimum use of the company’s resources
  • Evaluating and efficiently maneuvering various barriers to entry, improving profit margins, and extending its business in new, and existing markets

In the pharmaceutical manufacturing industry, Infiniti’s market entry analysis enables companies by providing in-depth insights into the barriers to entry discussed above and other potential obstacles. It also allows them to gain market share in their category and generate substantial savings. Additionally, market entry analysis provides companies with the information they need to develop or adopt strategic initiatives to overcome common challenges, such as regulatory issues or changing market dynamics.

To learn how market entry analysis addresses regulatory and intellectual property challenges in the pharmaceutical manufacturing industry, speak to our experts.

Pharma secondary packaging market

Infiniti’s Competitive Intelligence Solution for A Prominent Company in The Pharma Secondary Packaging Market: Exploring Key Packaging Innovations And competitive landscape Insights

In pharmaceuticals, secondary packaging constitutes the packaging which does not come in direct contact with the dosage form. Pharma secondary packaging is becoming widely adopted and essential as they offer critical functionalities, such as, for physical and barrier protection, secondary containment, adherence to regulations, and consumer safety. It also creates a buffer and protects primary packages from each other during transportation.

Business challenge

A prominent pharmaceutical company headquartered in San Francisco, CA sought to explore the changing trends in the secondary pharma packaging market by focusing the research on major design/technology innovations and best practices adopted by leading players in the pharma secondary packaging market. Through the engagement, the client wanted to support their future packaging developments and track industry trends over time. By leveraging Infiniti’s competitive intelligence solution, the pharmaceutical company wanted to understand the competitor landscape in the US and European pharma secondary packaging market, new features of secondary packaging being incorporated by competitors, product portfolio descriptions, and competitor strategies to promote adherence.   

Want comprehensive insights into the market drivers, challenges, key industry players, and more in the pharma secondary packaging market? Request a complimentary proposal.

Our Approach

Experts at Infiniti Research started by delving deeply into the pharma secondary packaging market transformation over the past decade in the US and Europe. This involved a well-balanced combination of primary and secondary research. Telephonic discussions were undertaken with over 45 respondents with expertise in the development, sales, marketing, and usage of products and services related to secondary packaging market such as pharmaceutical packaging specialists, packaging engineers, and packaging development experts. The secondary research undertaken by our analysts included comprehensive research materials from company websites, industry news CPA, HCPC, CHPA, packaging digest, and public database.

Through extensive competitive intelligence study and research methodologies, experts at Infiniti Research were able to identify the top pharma secondary packaging designs that are predominantly used. This includes medication adherence packaging, extended labels, and increasing use of sustainable materials in pharma secondary packaging. Furthermore, Infiniti’s competitor landscape assessment also identified some of the key competitors in the US and Europe, their respective packaging initiatives, and critical initiative undertaken to promote adherence.

With a focus to ensure product integrity, better manufacturing efficiency, and enhancing customer satisfaction, experts at Infiniti Research have identified that companies are developing innovative technologies such as thermochromic indicators and contemporary cartons designs. Furthermore, with Infiniti’s recommendation, the client adopted robotics and process automation that significantly improves production output, lowers operating cost, and enhances worker safety.

Business Impact

By leveraging Infiniti’s competitive intelligence solution, the client was able to successfully track their key market competitors and identify some of the most innovative and viable trends in the pharma secondary packaging market. Apart from this client was also able to:

  • Increase investments on their primary and secondary packaging lines by adopting technologies which result in faster turn-around time, fewer errors, and higher adaptability to incorporate and reproduce design changes
  • Collaborate with the CPO to formulate innovative packaging designs which are senior-friendly, child- resistant, medication adherence promoting, and offers unique dispensing mechanisms
  • Expedite early market entry for biologics and personalized medicine by identifying advancements such as 3D printing in pharmaceutical packaging
  • Reduce operational cost by 30% within this first quarter by adopting RPA into packaging operations
  • Focus on packaging designs that are cost-effective and have shorter production turnaround times
  • Incorporate adherence features in the secondary packaging design to help practitioners promote the use of the drugs to the patients
  • Build an effective planning and production process to minimize packaging errors and prevent product recalls, saving the company over $1.2 million within six months

For similar engagements for your business, get in touch with an industry expert

pharma M&A

Capturing Value from Pharma M&A: Critical Considerations for Success

The pharmaceutical industry is one of the major sectors that is actively involved in huge mergers and acquisition (M&A) deals, both in terms of numbers of deals and the amount of money spent. Most companies in the sector, especially the big pharma consider pharma M&A as a major factor to bolster innovation and overall growth. A recent research by our pharma industry experts shows that revenues coming from innovations sourced outside of Big Pharma is currently stands at over 45%. Over the years, several large, game-changing deals have continuously and profoundly changed the competitive landscape of the sector, while smaller yet significant transactions remain an integral part of pharma industry operations.

Why Pharma M&A is a driver of strategic repositioning?

Pharma M&A has become a common practice for companies that have non-diverse pipelines or have top revenue drugs that are nearing patent expiration and subsequent generic erosion. According to industry experts at Infiniti Research, some of key reasons why companies favor pharma M&A include:

  • The critical size requirements across various market segments have increased exponentially over the years. At this rate, it becomes nearly impossible for a single company for companies to survive on their own. This made strategic pharma M&A a necessity for most companies
  • Large mergers in the pharma industry allow bundling of sub-critical businesses, and thereby change the culture and to build new platforms
  • Another motivation for pharma M&A is to capture annual cost synergies by scaling up

For more insights on our portfolio of services for companies in the pharma industry

Consideration for successful M&A

Achieving Successful Integration Post Pharma M&A

Approximately only 60% of pharma merger deals succeed in the long run. A successful merger is one wherein the resulting company achieves the strategic intentions driving the merger when the deal was initially formed. Mergers that fail often show traits including focusing more attention on back-office integration, cost control, and systems consolidation.

Creating business synergies

Revenue increases during pharma M&A can often more difficult to achieve and take longer than expected. During pharma mergers and acquisitions teams must develop strategies such as the degree to which the existing portfolios need to be rationalized, how teams can be used to increase efficiency, how salesforce can be consolidated to remove overlap, and how the projects of each of the brands can be enhanced.

Defining the integration strategy

The successful integration of two companies largely depends on having a consistent approach with strategic intent. Guiding principles, priorities, and governance must reflect the logic behind the merger. A reliable integration strategy must be efficient in articulating both financial and nonfinancial goals, as well as risk-mitigation strategies.

Request a free proposal for more insights on how we can support your pharma M&A efforts.

Pharmaceutical blister packaging

Devising a Proprietary Procurement Model to Reduce Procurement Spend for a Pharmaceutical Blister Packaging Market Client

The global pharmaceutical blister packaging market is expected to expand through 2022, owing to the growth in over-the-counter (OTC) drugs, rising focus on health management, and outbreak of new diseases. Also, the rising demand for safe and tamper-evident packaging is anticipated to propel the pharmaceutical blister packaging market growth. In addition to this, the development of super barrier coating for blister packaging to protect ultra-sensitive drugs is boosting the demand for blister packaging in the pharmaceutical industry. However, with consumers becoming more conscious about the quality of pharmaceutical products and its visual appearance, companies in the pharmaceutical blister packaging market are in the need to ensure quality packaging while balancing the costs of production.

Top Markets: Europe holds the largest share in the pharmaceutical blister packaging market and is expected to retain its dominance through 2025. The experts at Infiniti Research predict that Latin American regions such as Brazil and Argentina will witness steady growth over the next two years.

In a world of complex supply chains and extreme price volatility, business leaders need valuable market insights to make smarter business decisions. Our procurement market intelligence solutions can help you achieve these business objectives. RFP for more insights.

Business Challenge

37

The client is a pharmaceutical blister packaging firm based out of North America. Due to the complex nature of the North American pharmaceutical blister packaging market, assessing the company’s overall procurement competence, evaluating suppliers’ pricing and cost structure, and conducting price model analysis was becoming difficult for the company. The pharmaceutical blister packaging client, therefore, wanted to gather data on supply market capabilities, understand how their competitors are managing supply chain operations, and identify key trends driving the market. In addition, they wanted help in developing a better contract negotiation strategy with current suppliers, reduce maverick spend, and enhance operational efficiency. They approached the experts at Infiniti Research to leverage their expertise in offering procurement market intelligence solution.

With Infiniti’s procurement market intelligence solution, the pharmaceutical blister packaging market client also wanted to tackle challenges including:

  • Extending product shelf life, maximizing production efficiency, and improving speed to market
  • Improving patient compliance
  • Creating visually appealing and texturally pleasing designs
  • Increasing visibility and accessibility
  • Protecting drugs from physical damage during transit
  • Customizing packaging to fit the needs of the product

Access to timely, accurate, and actionable market insights is a huge strategic advantage. Our procurement market intelligence experts can help you to gather real-time market and competitive insights. Contact us today.

Our Integrated Approach

To address the business issues and meet the specific requirements of the pharmaceutical blister packaging market client, the experts at Infiniti Research carried out an approach comprising of primary and secondary research. The data gathered through primary and secondary research was validated with market experts and independent consultants. Also, Infiniti’s procurement market intelligence engagement involved tracking the latest developments and procurement trends in the pharmaceutical blister packaging market through secondary journals. The experts also reached out to key stakeholders, thought leaders, and end-users of consulting services to understand their views on the pharmaceutical blister packaging market.

With the help of the procurement market intelligence study, the pharmaceutical blister packaging market client was able to identify their supplier’s cost and pricing structure and develop a sound price model analysis. Additionally, the experts helped the pharmaceutical blister packaging market client to develop a list of suppliers in terms of their business profile, financial structure, and revenue. This helped them to identify the right suppliers for providing them with the raw materials for production.

The experts at Infiniti Research also focused on estimating the current market size, market segments, the latest market trends, drivers, and challenges in the North American pharmaceutical blister packaging market.

Results Obtained

With Infiniti’s procurement market intelligence engagement, the pharmaceutical blister packaging market client was able to evaluate key suppliers’ cost structure and identify the right suppliers. This helped them to increase efficiency, improve compliance, and reduce operating costs. Also, the client was able to accurately analyze spend data and trends, which helped them to efficiently allocate operating budgets.

The procurement market intelligence experts at Infiniti Research also helped the client devise a sound contract negotiation strategy. This helped them to make better decisions regarding new and current suppliers. The experts also helped the client to understand how their competitors are managing supply chain operations. This helped them to strategize their supply chain initiatives and reduce maverick spend across inventory.

Also, by undertaking initiatives recommended by the experts at Infiniti Research, the pharmaceutical blister packaging market client was able to maximize production efficiency and improve speed to market. Understanding customers’ needs helped them to create visually appealing and texturally pleasing designs and drive patient engagement. Also, by using transparent packaging materials, they were able to increase visibility and accessibility.

In addition, the pharmaceutical blister packaging market client was able to preserve the integrity of pills by sequestering each pill inside its own blister in the blister pack. As recommended by the experts at Infiniti Research, the pharmaceutical blister packaging market client also used slim medication blister packs to ease the storage of pills and protect them from physical damage during transit.

By devising a proprietary procurement model, the experts helped the client to identify new cost reduction opportunities and reduce procurement spend by 20%.

34

Want to know more about our services for companies in the pharmaceutical blister packaging market? Request more info and our experts will get in touch with you with relevant insights.

Pharmaceutical industry

Generating Huge Sales and Realizing Profits of Over 29% for a Pharmaceutical Company Using Market Intelligence Engagement

Pharmaceutical Industry Analysis

The innovations in advanced biologics, rising population, and access to quality healthcare and pharmaceuticals to middle-class people worldwide are driving the growth of the global pharmaceutical industry. However, the fluctuating economy, legal issues, talent shortage, massive flow of generic medicines, and rising competition are expected to impact the growth prospect of the global pharmaceutical industry. Besides, companies in the pharmaceutical industry are facing decreasing return on investment due to price erosion in key markets. As such, companies in the pharmaceutical industry will need to foresee changing market dynamics and look for other markets to sustain growth.

Our market intelligence analysts can help you to assess profitable opportunities in new markets and provide the information you need to expand operations and accelerate growth. Request a FREE proposal today.

Business Challenge

The client is a pharma company based out of the United States.

As Canada is known to be one of the most profitable markets for pharmaceutical companies, the client wanted to expand their business operations to Canada. Before investing a huge sum into their expansion plan, they wanted to determine their growth potential and assess market opportunities in the Canadian pharmaceutical industry. They approached the experts at Infiniti Research to leverage their expertise in offering market intelligence engagement.

Other challenges that the client encountered were:

CaptureGovernment and security: As policies regarding the use of medicines varied in different countries, the client wanted to understand the policies in the Canadian pharmaceutical industry. In addition, they wanted to understand in-detail the procedure for new drug launch in Canada.

Massive flow of generic medicines: Due to the massive flow of less expensive or generic drugs in Canada, the client wanted to identify strategies to cut down on their production costs and gain a competitive edge.

Identifying the right set of customers: Before expanding their operations to Canada, they wanted to identify the profitable customers to focus on to drive sales.

Need for new and effective medicines: The client wanted to analyze competitors’ product offerings and identify drugs gaining popularity in the Canadian pharmaceutical industry. By doing so, they wanted to invest into similar drugs.

By identifying the potential for a new product or service, we help companies to make strategic business decisions and accelerate growth. Contact us today!

Our Approach

The experts at Infiniti Research followed a four-phased approach that involved:

CaptureMarket scanning and monitoring analysis to understand the regulatory changes in the Canadian pharmaceutical industry. This also involved evaluating the market potential for the client’s offerings in Canada and identifying the capital requirement for setting up new production and distribution units.

Technology assessment to spot the next technological breakthrough and identify cost-effective technologies to enhance the client’s operational efficiency.

Customer segmentation analysis to segregate customers into distinct target segments and identify profitable customer groups.

Competitive intelligence solution to analyze the product and service offerings of the top pharma companies in Canada.

Results Obtained

By understanding the current market dynamics and forecasting the potential business opportunities in the Canadian pharmaceutical industry, the client was able to devise a sound market entry plan. Also, by thoroughly understanding the procedures for launching a new product in Canada, they were able to succeed  clinical trials in their initial attempt. In addition, the adoption of cost-effective technologies helped the client to automate their operations and reduce production costs. This further helped them to reduce the costs of their drugs and better compete with generic drug manufacturers.

By identifying the right set of customers, the company in the pharma industry was able to personalize their marketing and sales efforts for them and generate maximum sales. Also, a detailed analysis of their competitors’ offerings helped them to competitively price their products. Within two years of entering the Canadian pharmaceutical industry, the client was able to generate huge sales and realize profits of over 29%.

Capture

Want to know more about our services for pharma companies? Request for more info and our experts will get in touch with you with comprehensive insights.

Pharma logistics

Identifying Critical Pharma Logistics Challenges in Canada

Every business endures pressure in terms of strict delivery schedules and meeting production efficiency. But when it comes to pharmaceuticals and healthcare product manufacturers, these deadlines become a matter of life and death, due to which ensuring product quality and timely deliveries are paramount for companies operating in this sector. This necessitates them to incorporate a changeover from existing pharma logistics strategies and traditional supply chain practices to new and innovative techniques to improve efficiency. Furthermore, in order to be adequately equipped to distribute pharmaceutical and healthcare products across Canada, pharma companies must be fully aware of the pharma logistics pain-points that the market has to offer.

As research and technology continue to fundamentally transform pharma capabilities, pharma logistics is being forced to adapt to changes in the types of products brought to the market. Request a free proposal to know how our experts can help you adapt to the changing trends in the pharma industry.

Large territories

Cold chains used for pharma logistics in Canada need to be highly robust due to the region’s vast territories. The region’s immense landscape provides challenging driving conditions including long distances, mountain winter conditions in the west, and unexpected weather scenarios that can result in roadblocks to effective delivery such as bridges ruined by rain, roads blocked by ice, and many other hazards. All of these factors have the potential to not only add to major transit delays but can also result in significant costs. Moreover, it can also prove to be difficult for pharma logistics providers to reach places up in the north due to limited infrastructure. In such territories, it may not be possible to place the pharmaceutical products on a direct flight to the required location, so the medicine may need to travel via truck for two days to complete the journey safely.

Extreme weather conditions

Temperatures can sometimes soar to extremes in Canada and this can sometimes compromise the quality of pharma products during transit. The pharma logistics facilities used must be able to protect the products from overheating in the hot climates or from freezing in the cold climates. This places a heavy burden on validating quality systems within the chain. The unpredictability of the weather conditions in Canada, in terms of their severity and duration, makes it extremely challenging for pharma logistics providers to preserve and ensure the quality and timely delivery of products.

Few industries face the scrutiny and demand for excellence as those engaged in pharma manufacturing. Get in touch with us to know more about our solutions for pharma companies and learn how we can help you stay in line with the advancements in the pharmaceutical industry.

Partnerships and collaborations

The pharmaceutical industry in Canada is rapidly moving towards an externalized R&D set up through partnerships and collaborations. A similar trend has been noted in the pharma logistics segment with several manufacturers outsourcing supply chain processes in an effort to benefit from the expertise of pharma logistics providers. However, this comes with challenges of its own. By delegating responsibilities externally, pharma manufacturers risk losing the end-to-end control that they once had on all their operations. Therefore, a stringent and robust quality agreement must be formed between all parties to protect the integrity of the product. Particularly well-defined standard operating procedures must be established regarding how the product and the raw materials will be treated. Cold chain partnerships with pharma logistics companies are largely a matter of trust. Once the cargo is handed to a forwarder or carrier, shippers must rely on their partners to safely steward their temperature-sensitive products through the cold chain. The success of these partnerships relies on effective communication. The best way to ensure effective monitoring of shipments is a truly collaborative approach, whereby all stakeholders charged with moving temperature-sensitive cargo work together to develop and implement the required programs.

Parallel Trade

The recent spate of selling pharmaceuticals from Canada into the US is only the tip of the iceberg. Canadian pharmaceutical companies were buying drugs at a lower price negotiated by the Canadian government and selling them across the border into the US where pricing is higher. This also occurs between borders in Europe between large wholesalers, as well as through black market transactions in developing countries. The danger here is that pharmaceutical companies lose the ability to know where these drugs are coming from. This can be largely avoided by the use of RFID technology.

Learn how you can enhance your pharma logistics capabilities.

Recent Posts

Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice